Renal Cell Carcinoma
Renal Cell Carcinoma
Advertisement
Emily MenendezLocalized Renal Cell Carcinoma | March 28, 2024
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
Read More
Emily MenendezAdvanced Renal Cell Carcinoma | March 22, 2024
Data from the JAVELIN Renal 101, KEYNOTE-426, CheckMate 9ER, CLEAR, and IMmotion151 trials were reviewed.
Gary Kirsh, MDProstate Cancer | March 22, 2024
Dr. Kirsh discusses his distinguished career and the evolution of urology practice in the United States.
Emily MenendeznccRCC | March 14, 2024
RMC has a 3-year survival rate of less than 5% and responds poorly to other treatments for renal malignancies.
Shuanzeng Wei, MD, PhDnccRCC | March 12, 2024
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
Emily MenendezLocalized Renal Cell Carcinoma | March 8, 2024
FASTRACK II was the first trial of its kind to examine nonsurgical definitive therapy in patients with primary RCC.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | March 6, 2024
Drs. Beckermann and Hutson compare the QOL data for tivozanib and belzutifan in patients with relapsed or refractory aRCC.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | March 6, 2024
Drs. Hutson and Beckermann summarize the long-term TIVO-3 data for patients with relapsed or refractory advanced RCC.
Daniel J. George, MD, FASCOAdvanced Renal Cell Carcinoma | March 6, 2024
Dr. George shares his expert opinion on the 8-year CheckMate 214 survival and durable response data in advanced RCC.
Daniel J. George, MD, FASCOAdvanced Renal Cell Carcinoma | March 6, 2024
Dr. George provides an overview of the adjuvant pembro long-term data and the other adjuvant approaches being investigated.
Leah LawrenceProstate Cancer | March 5, 2024
We spoke with clinicians about some of the disparities that exist, why they persist, and what might be done to correct them.
Akhil Abraham Saji, MDUrothelial Carcinoma | March 1, 2024
NARUS served as a platform for surgeons to share insights into the advancements and future directions of robotic surgery.
Zachary BessettenccRCC | March 11, 2024
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Katy MarshallAdvanced Renal Cell Carcinoma | February 21, 2024
Researchers analyzed the data from patients who received anti–LAG-3 and anti–PD-1.
Emily MenendezLocalized Renal Cell Carcinoma | February 15, 2024
While RLRN and TLRN procedures were found to have similar efficacy, TLRN also resulted in better surgical specimen integrity.
Saby George, MD, FACPAdvanced Renal Cell Carcinoma | March 7, 2024
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Saby George, MD, FACPAdvanced Renal Cell Carcinoma | March 7, 2024
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Thomas Powles, MBBS, MRCP, MDAdvanced Renal Cell Carcinoma | March 7, 2024
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel shared their excitement for the road ahead in kidney cancer.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
Advertisement
Advertisement
Advertisement